OverviewChartNewsTraderScreen

L&S Knock-Out AYJ 09.12.2024/  DE000LX30TD5  /

Lang & Schwarz
15/06/2024  13:03:29 Chg.0.00 Bid13:03:29 Ask13:03:29 Underlying Strike price Expiration date Option type
0.62EUR 0.00% 0.62
Bid Size: -		 0.78
Ask Size: -		 VALNEVA SE EO... 3.00 EUR 09/12/2024 Call
GlobeNewswire 05/06 Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Co...
GlobeNewswire 04/06 Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June
GlobeNewswire 03/06 Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases
GlobeNewswire 31/05 Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine
GlobeNewswire 21/05 Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer
GlobeNewswire 13/05 Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya...
GlobeNewswire 07/05 Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire 26/03 Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
GlobeNewswire 25/03 Valneva Announces Filing of 2023 Universal Registration Document and US Form 20-F
GlobeNewswire 21/03 Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th Wo...
GlobeNewswire 20/03 Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
GlobeNewswire 18/03 Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and Orbi...
GlobeNewswire 04/03 Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences
GlobeNewswire 29/02 U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHI...
GlobeNewswire 15/02 Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance
GlobeNewswire 05/02 Valneva Announces Sale of Priority Review Voucher for $103 Million
GlobeNewswire 10/01 Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine
GlobeNewswire 04/01 Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Foru...
GlobeNewswire 29/12/2023 Valneva Provides Updated 2023 Financial Guidance
GlobeNewswire 04/12/2023 Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, ...
GlobeNewswire 04/12/2023 Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine ...
GlobeNewswire 27/11/2023 EMA Accepts Valneva’s Chikungunya Vaccine Marketing Authorization Application for Accelerated Assess...
GlobeNewswire 15/11/2023 Valneva Announces the Availability of Documentation for its Extraordinary General Meeting including ...
GlobeNewswire 13/11/2023 Valneva Reports Positive Pivotal Phase 3 Immunogenicity Data in Adolescents for its Single-Shot Chik...
GlobeNewswire 10/11/2023 Valneva Announces U.S. FDA Approval of World’s First Chikungunya Vaccine, IXCHIQ®